- Home
- LFT vs BDTX Comparison
LFT vs BDTX Comparison
Compare LFT & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFT
- BDTX
- Stock Information
- Founded
- LFT 2012
- BDTX 2014
- Country
- LFT United States
- BDTX United States
- Employees
- LFT N/A
- BDTX N/A
- Industry
- LFT Real Estate Investment Trusts
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LFT Real Estate
- BDTX Health Care
- Exchange
- LFT Nasdaq
- BDTX Nasdaq
- Market Cap
- LFT 125.6M
- BDTX 132.5M
- IPO Year
- LFT N/A
- BDTX 2020
- Fundamental
- Price
- LFT $2.20
- BDTX $2.41
- Analyst Decision
- LFT Hold
- BDTX Strong Buy
- Analyst Count
- LFT 2
- BDTX 5
- Target Price
- LFT N/A
- BDTX $15.60
- AVG Volume (30 Days)
- LFT 376.6K
- BDTX 1.4M
- Earning Date
- LFT 08-11-2025
- BDTX 08-05-2025
- Dividend Yield
- LFT 14.68%
- BDTX N/A
- EPS Growth
- LFT N/A
- BDTX N/A
- EPS
- LFT 0.20
- BDTX 0.09
- Revenue
- LFT $27,066,283.00
- BDTX $70,000,000.00
- Revenue This Year
- LFT $152.58
- BDTX N/A
- Revenue Next Year
- LFT N/A
- BDTX N/A
- P/E Ratio
- LFT $10.95
- BDTX $27.30
- Revenue Growth
- LFT N/A
- BDTX N/A
- 52 Week Low
- LFT $2.16
- BDTX $1.20
- 52 Week High
- LFT $2.84
- BDTX $6.75
- Technical
- Relative Strength Index (RSI)
- LFT 30.32
- BDTX 57.88
- Support Level
- LFT $2.29
- BDTX $2.15
- Resistance Level
- LFT $2.63
- BDTX $2.71
- Average True Range (ATR)
- LFT 0.08
- BDTX 0.17
- MACD
- LFT -0.03
- BDTX -0.01
- Stochastic Oscillator
- LFT 8.14
- BDTX 55.36
About LFT Lument Finance Trust Inc.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.